Make an Inquiry
Accelerating Cancer Pain Drug Development

Pain and cancer represent some of the most complex and urgent therapeutic challenges in modern medicine, demanding innovative solutions and rigorous scientific advancement. Ace Therapeutics is a specialized partner in preclinical drug development, dedicated exclusively to advancing novel therapies for pain and cancer. Leveraging a comprehensive suite of preclinical services—from target validation and lead optimization to IND-enabling studies—Ace Therapeutics delivers integrated solutions that drive candidate selection and de-risk development pipelines. Our team combines deep scientific expertise with state-of-the-art platforms, including advanced in vivo and in vitro models tailored to the unique biology of pain and oncology targets. Ace Therapeutics operates with stringent adherence to global regulatory standards, ensuring robust, reproducible data and seamless progression toward clinical milestones. By uniting innovation, technical excellence, and regulatory rigor, Ace Therapeutics is committed to accelerating the translation of scientific discoveries into transformative therapeutics for patients living with pain and cancer.

What is Cancer PainTargets for Cancer PainDrug Discovery and Development ServicesWhy Choose Us

What is Cancer Pain

Cancer pain is a complex clinical syndrome resulting from the direct or indirect effects of malignant disease and its treatments. The etiology involves tumor infiltration of bones, nerves, or internal organs, as well as pain induced by interventions such as surgery, chemotherapy, or radiotherapy. Pathophysiologically, cancer pain encompasses both nociceptive mechanisms—stemming from tissue damage and inflammation—and neuropathic mechanisms due to nerve injury or dysfunction. This multifaceted process leads to the activation of pain pathways and persistent, often severe, discomfort that significantly impacts patients’ lives. Clinically, cancer pain presents with diverse manifestations, including somatic pain (well-localized, aching or throbbing), visceral pain (deep, cramping or pressure-like), neuropathic pain (burning, shooting, or electric shock-like), and breakthrough pain (sudden, intense episodes). Diagnosis relies on thorough patient history, physical examination, and the use of standardized pain assessment tools, supplemented by imaging and laboratory studies to identify underlying causes. Effective management requires a multimodal approach, incorporating opioid analgesics such as morphine, fentanyl, oxycodone, and methadone; adjuvant therapies like nabiximols (cannabis extract); nonsteroidal anti-inflammatory drugs (e.g., diclofenac); and multidisciplinary care to address both physical and psychological aspects, aiming to improve quality of life and functional outcomes.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-175591-09-0175591-23-8-free-base-tapentadol-hydrochloride-rec-innm-usan tapentadol hydrochloride (Rec INNM; USAN) 175591-09-0; 175591-23-8 (free base) C14 H23 N O . Cl H 257.799
Cannabis sativa L. extract; nabiximols (USAN) 56575-23-6
img-52-26-6-morphine-hydrochloridethebametten morphine hydrochloride; thebametten 52-26-6 C17 H19 N O3 . Cl H 321.799
img-437-38-7-fentanyl-rec-inn-usan-ban-janfentanyl-sdi fentanyl (Rec INN; USAN; BAN; JAN); fentanyl SDI 437-38-7 C22 H28 N2 O 336.471
img-36282-47-0-tramadol-hydrochloride-rec-innm-usan-banm tramadol hydrochloride (Rec INNM; USAN; BANM) 36282-47-0 C16 H25 N O2 . Cl H 299.836
img-15307-79-615307-86-5-free-acid-diclofenac-sodium-rec-innm-usan-banm-jan diclofenac sodium (Rec INNM; USAN; BANM; JAN) 15307-79-6; 15307-86-5 (free acid) C14 H10 Cl2 N O2 . Na 318.13
img-437-38-7-free-base990-73-8-fentanyl-citrate-rec-innm-usan-banm-jan fentanyl citrate (Rec INNM; USAN; BANM; JAN) 437-38-7 (free base); 990-73-8 C22 H28 N2 O . C6 H8 O7 528.594
img-1095-90-576-99-3-free-base-methadonemethadone-hydrochloride-rec-innm-usan-ban methadone; methadone hydrochloride (Rec INNM; USAN; BANM) 1095-90-5; 76-99-3 (free base) C21 H27 N O . Cl H 345.906
img-124-90-376-42-6-free-base-oxycodone-hydrochloride-rec-innm-usan-banm-jan oxycodone hydrochloride (Rec INNM; USAN; BANM; JAN) 124-90-3; 76-42-6 (free base) C18 H21 N O4 . Cl H 351.825
img-unknown-morphine-sulfate-usan-banm-janmorphine-sulphate morphine sulfate (USAN; BANM; JAN); morphine sulphate 2 C17 H19 N O3 . 5 H2 O . H2 O4 S 758.83

Learn More

Targets for Cancer Pain

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Acid-Sensing Ion Channel (ASIC) (nonspecified subtype)
Cannabinoid receptor (nonspecified subtype)
opioid receptor mu 1 OPRM1
Opioid receptor (nonspecified subtype)
NMDA receptor
solute carrier family 6 member 4 SLC6A4
prostaglandin-endoperoxide synthase 2 PTGS2
prostaglandin-endoperoxide synthase 1 PTGS1
solute carrier family 6 member 2 SLC6A2
opioid related nociceptin receptor 1 OPRL1

Cancer pain arises from a complex interplay of molecular targets involved in nociceptive, inflammatory, and neuropathic pathways. Key targets include the opioid receptors (mu, delta, and kappa subtypes), which mediate analgesia by inhibiting neuronal excitability and neurotransmitter release. Cannabinoid receptors (CNR1 and CNR2) and the orphan GPCR GPR55 modulate nociceptive and inflammatory signaling, providing alternative pathways for pain control. Prostaglandin-endoperoxide synthases (PTGS1/COX-1 and PTGS2/COX-2) are central to inflammatory pain, driving prostaglandin production and sensitization of pain pathways. Nerve growth factor (NGF) promotes neuronal sensitization and sprouting, while sodium channel Nav1.7 (encoded by SCN9A) enhances neuronal excitability and contributes to spontaneous pain. Together, these targets orchestrate the multifaceted mechanisms underlying cancer-induced pain.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates cancer pain drug discovery by offering robust, sensitive platforms to evaluate candidate analgesics. We provide comprehensive assays targeting opioid receptors (mu, delta, kappa), voltage-gated sodium channels, prostaglandin synthases, and monoamine transporters. Utilizing advanced methodologies—including radioligand binding, patch-clamp electrophysiology, BRET, cAMP, ELISA, and molecular profiling—we assess potency, efficacy, selectivity, and mechanism of action. Quantification of parameters such as EC50, IC50, Ki, and pKi supports lead optimization and decision-making. Our reliable, reproducible data empower preclinical development of novel, effective cancer pain therapeutics.

Opioid Receptor Delta 1 Opioid Receptor Kappa 1
Opioid Receptor Mu 1 Prostaglandin-Endoperoxide Synthase 1
Prostaglandin-Endoperoxide Synthase 2 Sodium Voltage-Gated Channel Alpha Subunit 5
Sodium Voltage-Gated Channel Alpha Subunit 9 Solute Carrier Family 6 Member 2
Solute Carrier Family 6 Member 4

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to driving innovation in the fields of pain and cancer therapeutics through our specialized expertise in research and drug development. Our professional teams consist of highly experienced scientists and industry experts who leverage advanced technology platforms to accelerate the discovery and optimization of new therapeutics. With a proven track record in delivering reliable preclinical drug development services, Ace Therapeutics has become a trusted partner for organizations seeking to bring novel pain and cancer treatments to market. We uphold the highest quality standards and ensure strict regulatory compliance at every stage of the development process, providing our clients with confidence in the integrity and reproducibility of our results. Ace Therapeutics is deeply committed to advancing the field of pain and cancer therapeutics, and we work tirelessly to support the success of our partners and ultimately improve patient outcomes. Choosing Ace Therapeutics means choosing professionalism, reliability, and a shared vision for a healthier future.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for pain and cancer?

A: Preclinical research for pain and cancer drugs faces unique challenges, such as developing and validating relevant animal models that accurately mimic human disease states and pain responses, as well as the heterogeneity and complexity of cancer biology. For pain, subjective endpoints and translational gaps between animal behavior and human experience are significant hurdles. For cancer, tumor microenvironment, metastasis, and resistance mechanisms must be considered. Our company addresses these challenges by utilizing a broad portfolio of validated models, advanced imaging, and molecular profiling techniques to ensure robust and predictive preclinical data.

Q: What are the key regulatory considerations for preclinical development of pain and cancer therapeutics?

A: Regulatory agencies such as the FDA and EMA have specific requirements for preclinical data supporting IND/CTA submissions for pain and cancer drugs. For pain therapeutics, regulatory guidance emphasizes the need for robust efficacy, safety, and abuse liability data. For cancer drugs, requirements include comprehensive pharmacology, toxicology, and proof-of-concept efficacy studies, often in multiple tumor models. Our team is experienced in designing and executing GLP-compliant studies and preparing regulatory documentation to facilitate smooth interactions with regulatory authorities.

Q: What technical aspects should be considered in preclinical research for pain and cancer drug candidates?

A: For pain, technical considerations include selection of appropriate pain models (neuropathic, inflammatory, etc.), behavioral assays, and biomarkers for mechanism-of-action studies. For cancer, technical aspects involve choosing relevant cell lines and xenograft models, molecular characterization, pharmacokinetic/pharmacodynamic (PK/PD) analyses, and immuno-oncology assays. Our company offers state-of-the-art technical platforms, including in vivo imaging, high-throughput screening, and advanced molecular biology tools to support comprehensive preclinical evaluation.

Q: What are the typical timelines and cost considerations for preclinical development of pain and cancer drugs?

A: Preclinical development timelines for pain and cancer drugs typically range from 12 to 24 months, depending on the complexity of the program and regulatory requirements. Costs vary widely based on the number and type of studies, but can range from several hundred thousand to several million dollars. Our company provides detailed project planning, cost estimates, and flexible service packages to optimize resource allocation and accelerate timelines while maintaining high scientific and regulatory standards.

Q: What are the critical success factors in preclinical drug development for pain and cancer indications?

A: Key success factors include selecting the right targets and models, generating high-quality and reproducible data, early identification of safety liabilities, and strong translational strategies to bridge preclinical and clinical findings. Collaboration with experienced partners who understand the scientific, technical, and regulatory landscape is essential. Our multidisciplinary team ensures integrated project management, scientific rigor, and regulatory compliance, maximizing the likelihood of successful IND/CTA submissions and clinical progression.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.